Page 1

TSCAN THERAPEUTICS TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress November 10 , 2021 IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR - T Therapy Candidates TSC - 100 and TSC - 101 Lead TCR Identified for TSC - 200 Solid Tumor Program Targeting HPV16 ; TCR Advancing into IND - Enabling Activities with IND Submission Planned for Second Half of 2022 New Solid Tumor Program , TSC - 204 , Established Based on a TCR Targeting an HLA - C * 07 : 02 Epitope of MAGE - A1 WALTHAM , Mass . , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- TScan Therapeutics , Inc. ( Nasdaq : TCRX ) , a biopharmaceutical company focused on the development of T - cell receptor ( TCR ) engineered T cell ( TCR - T ) therapies for the treatment of patients with cancer , today reported financial results for the quarter ended September 30 , 2021 , highlighted recent program progress , and outlined key upcoming expected milestones . " Throughout the third quarter of 2021 , we've continued to execute on our long - term goals of advancing transformational TCR - T therapy candidates and expect to file IND applications for our lead liquid tumor candidates TSC - 100 and TSC - 101 by the end of the year , " said David Southwell , President and Chief Executive Officer of TScan Therapeutics . " We look forward to sharing additional details of our liquid tumor program at the American Society of Hematology Annual Meeting and Exposition . We also made significant progress across our solid tumor pipeline , particularly the advancement of TSC - 200 into IND - enabling studies and the launch of a new TCR program based on the discovery of a novel epitope on the validated solid tumor target MAGE - A1 . " Third Quarter 2021 and Recent Business Highlights • TScan recently announced that two abstracts related to lead liquid tumor TCR - T therapy candidates TSC - 100 and TSC - 101 have been accepted for poster presentations at the upcoming American Society of Hematology ( ASH ) Annual Meeting and Exposition being held from December 11-14 , 2021 . • During the third quarter , TScan advanced a lead TCR - T therapy candidate for its TSC - 200 program for HPV16 into investigational new drug ( IND ) -enabling activities and plans to submit an IND for this program in the second half of 2022 . HPV is a validated cancer target found in HPV - positive tumors , including many cases of head & neck and cervical cancers . Using its proprietary ReceptorScan and TargetScan platforms , TScan screened over half a billion T cells from a variety of human donors to identify a naturally occurring , ultra - high affinity TCR that recognizes an HLA - A * 02 : 01 - restricted epitope derived from the E7 protein of HPV16 . Previously , clinical data from the National Cancer Institute ( NCI ) demonstrated a favorable safety and efficacy profile for an HPV TCR . TScan intends to build on the positive NCI results by developing an enhanced autologous TCR - T therapy using its T - Integrate cell manufacturing platform and by multiplexing its HPV TCR with additional TCRs in its TSC - 2xx series of cell therapy candidates . TScan has used the large cargo capacity of T - Integrate to include in the TSC - 200 construct features that enable engineering of both cytotoxic and helper T cells and features designed to help confer resistance to the immunosuppressive micro - environment of solid tumors . • TScan has recently discovered a novel HLA - C * 07 : 02 - restricted epitope encoded by the well - known cancer / testis gene MAGE - A1 , using its TargetScan platform . This cancer - specific gene is frequently overexpressed in a wide variety of solid tumors . In the U.S. , the target is expressed in as many as 45 % of head & neck cancer patients , 50 % of melanoma patients , 50 % of cervical cancer patients and 50 % of non - small cell lung cancer patients . The TCR that recognizes this novel epitope was isolated from a patient with head & neck cancer who exhibited an exceptional response to immune checkpoint inhibitor therapy . TScan has launched a new program , TSC - 204 , that will include multiple TCRs for different HLA - restricted epitopes on this same protein . TScan believes that it is the only company with a disclosed TCR program in MAGE - A1 for HLA types other than A * 02 : 01 . The Company has now advanced TSC - 204 into lead TCR - T therapy candidate optimization . • The Company expanded its management team with the appointments of Zoran Zdraveski , J.D. , Ph.D. , as Chief Legal Officer , and Heather Savelle as Vice President , Investor Relations . • In July 2021 , TScan completed its initial public offering ( IPO ) , raising $ 100 million in aggregate gross proceeds , before deducting underwriting discounts and commissions and offering expenses , and began trading on The Nasdaq Global Market . The IPO followed the closing of a Series C preferred stock financing of $ 100 million in gross proceeds in January 2021 .